Videos

Lori Wirth, MD, discusses the mechanism of action of selpercatinib and key data from the LIBRETTO-001 and LIBRETTO-531 clinical trials.

Experts in the management of thyroid cancer share their treatment recommendations for a 60-year-old man with RET+ metastatic medullary thyroid cancer.

The panel of experts discuss the importance of molecular testing and RET mutations in thyroid cancer disease management.

Dr Wirth reviews disease management considerations a 60-year-old man with RET+ metastatic medullary thyroid cancer.

Lori Wirth, MD, and Andrew Gianoukakis, MD, discuss patient and clinical characteristics necessitating thyroidectomy in patients with thyroid cancer.

Lori Wirth, MD, presents the case of a 60-year-old man with RET+ metastatic medullary thyroid cancer.

Luhua Wang, MD, discussed the impact that the approval of the CAR T-cell therapy brexucabtagene autoleucel has had on mantle cell lymphoma.

Drs Shadman and Cohen discuss clinical trial data utilizing acalabrutinib in B-cell lymphomas.

Two experts compare experiences and data concerning use of ibrutinib, acalabrutinib, and zanubrutinib in B-cell lymphomas.

Solange Peters, MD, PhD, the president of the European Society of Medical Oncology, discusses the use of immunotherapy for the treatment of mesothelioma.

An expert breaks down therapy sequencing in metastatic colorectal cancer and provides some clinical pearls.

Kanwal Raghav, MBBS, MD, explains the rationale for using regorafenib for metastatic colorectal cancer and reviews data from 2 clinical trials.

An oncologist reviews the maintenance therapy options in metastatic colorectal cancer and what clinical findings can lead to a change in therapies.

Kanwal Raghav, MBBS, MD, presents the case of a 72-year-old woman with metastatic colorectal cancer and describes the first-line therapy options.

Rachel Wuerstein, MD, of the Unïversität Müchen, discusses the differences between the global and Asian cohorts in the KAMILLA trial (NCT01702571), which evaluates the benefit of trastuzumab emtansine (T-DM1, Kadcyla) in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.

Jason Westin, MD, discusses the current standard of care in diffuse large B-cell lymphoma.

Krina K. Patel, MD, MSc, discusses how she chooses treatment for her patients with early or late relapsed/refractory multiple myeloma.

PARP inhibitors are a common treatment for ovarian cancer, but mechanisms of resistance have yet to be fully understood.

Marcia Brose, MD, discusses the efficacy and safety data of a phase 2 trial examining lenvatinib dose reductions in patients with RAI-DTC.

Andrew Gianoukakis, MD, and Lori Wirth, MD, examine post-hoc analysis data from the phase 3 SELECT trial.

Drs Shadman and Cohen provide an overview of clinical trials utilizing the BTK inhibitor, ibrutinib, for B-cell lymphomas.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, introduce available BTK inhibitors used as targeted therapy in B-cell malignancies.

The doctors switch their monoclonal antibody conversation’s focus to longcastuximab tesirine for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

The discussion of tafasitamab as a monoclonal antibody therapy option for relapsed/refractory diffuse large B-cell lymphoma continues.

Considerations for future unmet needs and novel therapies in multiple myeloma, followed by practical advice for community oncologists.

In the context of multiple myeloma, Peter Voorhees, MD, considers the role of doublet vs triplet therapy, initial therapy selection, and monitoring treatment response.

Peter Voorhees, MD, reflects on practical implications of the MAIA trial and how best to manage a patient with newly diagnosed multiple myeloma.

Updated results from the MAIA trial, which tested the addition of daratumumab to lenalidomide-dexamethasone therapy in patients with transplant-ineligible newly diagnosed multiple myeloma.

Expert insight on the optimal management of transplant-ineligible newly diagnosed multiple myeloma in light of available therapies and clinical data.

Peter Voorhees, MD, provides a broad overview on risk assessment and the goals of therapy in multiple myeloma management.